RT Journal Article
SR Electronic
T1 Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.05.20113738
DO 10.1101/2020.06.05.20113738
A1 Moreno-García, Estela
A1 Rico, Verónica
A1 Albiach, Laia
A1 Agüero, Daiana
A1 Ambrosioni, Juan
A1 Bodro, Marta
A1 Cardozo, Celia
A1 Chumbita, Mariana
A1 De la Mora, Lorena
A1 García-Pouton, Nicole
A1 Garcia-Vidal, Carolina
A1 González-Cordón, Ana
A1 Hernández-Meneses, Marta
A1 Inciarte, Alexy
A1 Laguno, Montse
A1 Leal, Lorna
A1 Linares, Laura
A1 Macaya, Irene
A1 Meira, Fernanda
A1 Mensa, Josep
A1 Moreno, Antonio
A1 Morata, Laura
A1 Puerta-Alcalde, Pedro
A1 Rojas, Jhon
A1 Solá, Montse
A1 Torres, Berta
A1 Torres, Manuel
A1 Tomé, Adrià
A1 Castro, Pedro
A1 Fernández, Sara
A1 Nicolás, Josep Maria
A1 Almuedo-Riera, Alex
A1 Muñoz, Jose
A1 Fernandez-Pittol, Mariana Jose
A1 Marcos, Maria Angeles
A1 Soy, Dolors
A1 Martínez, José Antonio
A1 García, Felipe
A1 Soriano, Alex
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.06.05.20113738.abstract
AB Background In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation of ICU beds has been one of the major burdens in the management worldwide; therefore, clinical strategies to avoid ICU admission are needed.Objective We aimed to describe the influence of tocilizumab on the need of transfer to ICU or death in non-critically ill patients.Methods A retrospective study of 171 patients with SARS-CoV-2 infection that did not qualify as requiring transfer to ICU during the first 24h after admission to a conventional ward, were included. The criteria to receive tocilizumab was radiological impairment, oxygen demand or an increasing of inflammatory parameters, however, the ultimate decision was left to the attending physician judgement. The primary outcome was the need of ICU admission or death whichever came first.Results 77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, P= 0.005) and need of invasive ventilation (0 vs 13.8%, P=0.001). In multivariable analysis, tocilizumab remained as a protective variable (OR: 0.03, CI 95%: 0.007-0·1, P=0.0001) of ICU admission or death.Conclusion Tocilizumab in the early stages of the inflammatory flare, could reduce ICU admissions and mechanical ventilation use. The mortality rate of 10.3% among patients receiving tocilizumab appears to be lower than other reports.Clinical implication Our results suggest that tocilizumab administered to non-critically ill patients could reduce ICU admissions and mortality.Capsule summary Tocilizumab administered to non-critically ill patients with SARS-CoV-2 infection in the early stages of the inflammatory flare, could reduce an important number of ICU admissions and mechanical ventilation use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committee of the Hospital Clinic of Barcelona approved the study and due to the nature of retrospective chart review, waived the need for inform consent from individual patients (Comite Etic Investigacio Clinica; HCB/2020/0273).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study will be available upon request to the corresponding author.